Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Total Debt (2022 - 2025)

Historic Total Debt for Immunocore Holdings (IMCR) over the last 4 years, with Q3 2025 value amounting to $392.6 million.

  • Immunocore Holdings' Total Debt rose 53.75% to $392.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $392.6 million, marking a year-over-year increase of 53.75%. This contributed to the annual value of $391.0 million for FY2024, which is 71442.38% up from last year.
  • Latest data reveals that Immunocore Holdings reported Total Debt of $392.6 million as of Q3 2025, which was up 53.75% from $392.1 million recorded in Q2 2025.
  • In the past 5 years, Immunocore Holdings' Total Debt ranged from a high of $438.1 million in Q2 2024 and a low of $47.8 million during Q4 2022
  • Over the past 4 years, Immunocore Holdings' median Total Debt value was $391.5 million (recorded in 2025), while the average stood at $325.5 million.
  • As far as peak fluctuations go, Immunocore Holdings' Total Debt skyrocketed by 71442.38% in 2024, and later tumbled by 1051.64% in 2025.
  • Quarter analysis of 4 years shows Immunocore Holdings' Total Debt stood at $47.8 million in 2022, then increased by 0.43% to $48.0 million in 2023, then soared by 714.42% to $391.0 million in 2024, then grew by 0.4% to $392.6 million in 2025.
  • Its Total Debt was $392.6 million in Q3 2025, compared to $392.1 million in Q2 2025 and $391.5 million in Q1 2025.